Havells India Ltd. announces a new order win

The ₹879 Cr Noida R&D centre should be viewed as a multi-year project commitment, not a single-year addition to FY25 or FY26 capex. It is large relative to the company’s historical capex run-rate, but the FY25/FY26 guidance figures themselves could not be confirmed from the cited disclosures.

† The FY25 figure is inconsistent within the same source, which cites both ₹7.2 billion and ₹7.7 billion; therefore, the FY25 comparison should be treated as directional.

Implication: the ₹879 Cr project is approximately 4.4 times the ₹200 Cr R&D allocation referenced in the FY27 capex plan, derived from ₹879 Cr ^[3] divided by approximately ₹200 Cr ^[4]. This is consistent with the earlier annual allocation representing only the initial or one-year spend, while the ₹879 Cr represents the broader project cost.

Cash-outflow timeline: management’s disclosed description is only “over the next few years” ^[3]. No year-by-year capex phasing, construction completion date, or precise cash-outflow schedule has been provided. Accordingly, the evidence supports a staggered cash outflow rather than a ₹879 Cr FY27 cash charge. The Uttar Pradesh incentive is capped at ₹25 Cr per year ^[5], but its timing and eligibility-based reimbursement cannot be used to calculate the project’s net cash outflow schedule.

The disclosed terms point to a capex-linked incentive, but the accounting treatment is not yet confirmed. It would be premature to book the full potential benefit as either a reduction in asset cost or operating income.

Terms reported

• Havells received a Letter of Comfort dated 5 November 2026 from Invest UP under the Uttar Pradesh Global Capability Centres Policy 2024 for its proposed Centre of Excellence/R&D facility in Noida. The proposed investment is ₹879 Cr over the next few years. ^[3]
• The incentive is reported at up to 25% of eligible capital expenditure, subject to a ceiling of ₹25 Cr per year. ^[5]
• Accordingly, ₹879 Cr is the proposed project investment—not the incentive amount. The eventual benefit cannot be calculated from the headline investment alone because the eligible-capex base, claim period, and satisfaction of policy conditions are not specified. ^[5]

Expected financial-statement treatment

The accounting treatment could not be confirmed from the announcement. In particular, it does not establish whether Havells will:

1. deduct the eligible incentive from the carrying cost of the R&D-centre assets; 2. present it as deferred income and recognize it over the relevant asset-use period; or 3. recognize it as an operating grant in the income statement.

Analyst read: The linkage to eligible capital expenditure makes the incentive appear more consistent with an asset-related/capital incentive than with a recurring operating grant. However, even if classified as asset-related, the final presentation—asset-cost reduction versus deferred-income accounting—depends on the executed grant terms, conditions, management’s accounting policy and the point at which receipt becomes sufficiently certain.

The Letter of Comfort should therefore not be interpreted as an immediately recognized ₹25 Cr annual benefit or as a confirmed reduction in FY27 expenses. The decisive disclosure will be Havells’ subsequent accounting-policy note or financial-statement treatment once the project, eligible expenditure and incentive claims progress.

The ₹879 Cr Noida R&D centre is a large multi-year capital commitment, but it should not be treated as one year’s R&D expense. It is equivalent to about 2.8x Havells’ FY26 R&D investment and 3.9% of FY26 revenue on an aggregate basis. The actual annualised R&D intensity will depend on the construction and spending timeline.

Havells: R&D intensity has been rising

Havells reported ₹317 Cr of R&D investment in FY26 ^[6]. Against FY26 consolidated revenue of ₹22,527.8 Cr ^[7], this equates to approximately 1.4% of revenue, consistent with the reported series. Using the reported ₹879 Cr proposed outlay ^[3], the FY26 R&D investment ^[6] and FY26 revenue ^[7], the outlay is derived at 2.8x one year of FY26 R&D spending and 3.9% of one FY26 revenue.

Interpretation: Havells’ recurring R&D intensity has increased from 0.8% in FY22 to 1.4% in FY26, a 0.6 percentage-point increase. However, the Noida project is a capital investment spread over “the next few years”, rather than an immediate move to 3.9% annual R&D intensity. For illustration, spread over three years it would represent roughly ₹293 Cr per year, or 1.3% of FY26 revenue; over four years, roughly ₹220 Cr per year, or 1.0%. These are mechanical scenarios, not company guidance.

Peer benchmark: R&D-specific comparison is not confirmed

The cited material does not provide a directly comparable R&D-expense percentage for Crompton or Polycab. The closest common measure is total capex-to-revenue, which includes manufacturing capacity, expansion and other capital expenditure—not just R&D.

Company-specific read

• Crompton: Its FY26 total capex intensity was substantially lower than Havells’—1.0% versus 6.6% of revenue ^{[10] [8]}. That suggests a more asset-light capital-allocation profile in FY26, but it does not establish that Crompton spends less on R&D because an R&D-specific figure could not be confirmed.
• Polycab: Its total capex intensity was closer to Havells at 5.1% of revenue, versus Havells’ 6.6% ^{[12] [8]}. Polycab therefore appears closer on broad capital intensity, but the comparison still cannot be converted into an R&D ranking without separating R&D from plant, capacity and other capex.

Bottom line: Havells is clearly stepping up innovation spending: recurring R&D intensity has reached 1.4% of revenue, while the Noida centre adds a sizeable multi-year investment equivalent to nearly three years of FY26 R&D spending. Against peers, Havells screens as more capital-intensive than Crompton and modestly more capital-intensive than Polycab on total FY26 capex, but a definitive R&D-intensity ranking is not supported by the cited peer disclosures.